{
  "abstract": "Isocitrate dehydrogenase (IDH)-mutant gliomas are primary malignant brain tumors that predominantly affect young adults, and are characterized by relatively favorable clinical outcomes compared with other brain malignancies. Despite advances in molecular classification and multimodal treatment, tumor recurrence remains inevitable in most patients, raising fundamental questions about the true extent of disease and the biological basis of recurrence. A recent study identified rare IDH1 mutation-bearing cells within histologically and radiologically normal peritumoral cortex, suggesting that the earliest stages of gliomagenesis may extend beyond the conventionally defined tumor margin. This observation suggests that these mutation-bearing cortical cells may contribute to tumor recurrence even after gross total resection and supports the potential value of early therapeutic intervention targeting these latent cells, such as with IDH inhibitors, to delay disease progression. Collectively, these insights suggest that IDH-mutant gliomas may be better understood as a spatially extended biological process rather than a strictly localized lesion. A more integrated approach that combines precise surgical techniques with molecularly informed therapies may improve long-term disease control.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Anatomy, College of Medicine, The Catholic University of Korea, Seoul, Korea .",
    "Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Korea ."
  ],
  "article_type": "review article",
  "arxiv": null,
  "author_total": 1,
  "authors": [
    {
      "affs": [
        0,
        1
      ],
      "name": "Jung Won Park",
      "orcid": "0000-0002-5300-3745"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/fhgk0kwc16dxe.bib",
  "cited_by": 0,
  "doi": "10.14791/btrt.2026.0018",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13744892/",
  "id": "fhgk0kwc16dxe",
  "issns": [
    "2288-2405",
    "2288-2413"
  ],
  "landing_url": "https://doi.org/10.14791/btrt.2026.0018",
  "language": "en",
  "licence": "CC-BY-NC-4.0",
  "licence_label": "CC BY-NC 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "KSNO Contribution"
    ],
    [
      "heading",
      "Review Article"
    ],
    [
      "openalex",
      "2730|Glioma Diagnosis and Treatment"
    ]
  ],
  "openalex": "W7223655103",
  "pdf_url": null,
  "pmcid": "PMC13744892",
  "pmid": "42984241",
  "published": "2026-10-22",
  "publisher": "Korean Brain Tumor Society",
  "ris": "https://research.draconitic.com/paper/fhgk0kwc16dxe.ris",
  "sources": [
    {
      "first_seen": "2026-11-11T12:22:21Z",
      "native_id": "PMC13744892",
      "source": "pmc",
      "url": "https://doi.org/10.14791/btrt.2026.0018"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2730|Glioma Diagnosis and Treatment",
      "subfield": "oncology"
    }
  ],
  "title": "From Cellular Origin to Clinical Recurrence: Rethinking Tumor Boundaries in Isocitrate Dehydrogenase-Mutant Gliomas",
  "title_text": "From Cellular Origin to Clinical Recurrence: Rethinking Tumor Boundaries in Isocitrate Dehydrogenase-Mutant Gliomas",
  "type": "peer-reviewed",
  "updated_at": "2026-11-12T12:21:18Z",
  "url": "https://research.draconitic.com/paper/fhgk0kwc16dxe",
  "venue": "Brain Tumor Research and Treatment",
  "versions": []
}